Article Text

Download PDFPDF
A novel early-stage orthotopic model for ovarian cancer in the Fischer 344 rat
  1. K. D. Sloan Stakleff*,
  2. A. G. Rouse,
  3. A. P. Ryan,
  4. N. A. Haller* and
  5. V. E. Von Gruenigen,§
  1. * Kenneth Calhoun Research Laboratory, Akron General Medical Center, Akron, Ohio
  2. Department of Obstetrics and Gynecology, Akron General Medical Center, Akron, Ohio
  3. § Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Northeastern Ohio Universities College of Medicine, Rootstown, Ohio
  1. Address correspondence and reprint requests to: Kimberly D. Sloan Stakleff, MS, Kenneth Calhoun Research Laboratory, Akron General Medical Center, 400 Wabash Avenue, Akron, OH 44307, USA. Email: kstakleff{at}


The purpose of our study was to ascertain the progression of metastases in a novel ovarian cancer model designed to mimic early-stage disease by utilizing an orthotopic injection technique. Female Fischer 344 rats were injected with either 104 or 105 NuTu-19 cells by intraperitoneal or orthotopic injection. Peritoneal washings and histologic specimens were examined to correlate the incidence and extent of tumor growth. In a second phase, orthotopic injections of 102 and 103 cells were compared to that of 104 cells. Progression of ovarian cancer was observed by gross and microscopic examinations in both intraperitoneal and orthotopic models. Pelvic extension and abdominal adhesions uniquely characterized the orthotopically injected animals. Numbers of identifiable metastases declined with lower cell inocula, confirming that early-stage disease was extended to at least 14 days with 102 NuTu-19 cells. The orthotopic ovarian cancer model emulates early disease with the initiation of a primary tumor that is localized within the inherent microenvironment. The orthotopic model offers a clinically relevant alternative for future cancer research that allows for the investigation of therapeutic strategies against early stages of the disease process.

  • Fischer 344 rats
  • orthotopic
  • ovarian cancer

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.